COMPOSITION AND METHODS FOR RECTAL DELIVERY OF 4-AAPA AND 5-ASA COMPOUNDS
The invention, in various aspects and embodiments, provides compositions and methods for treating or preventing inflammation of the lower gastrointestinal tract. The compositions and methods in various embodiments relate to rectal administration of pharmaceutical compositions that comprise an agent that forms one or more 4-AAPA compounds or 5-ASA compounds by azo reduction. In various embodiments, the compositions and methods treat, reduce, or prevent inflammation of the colon and/or rectum, as well as in some embodiments, an ileo-anal pouch in a subject. Compositions for rectal administration can be formulated as emulsions, suppositories (both suspension and solid), gels, and foam and foamable pharmaceutical compositions.
1 . A method of treating or preventing inflammation of the lower gastrointestinal tract in a subject, comprising rectally administering an effective amount of a pharmaceutical composition comprising an agent that forms one or more 4-AAPA compounds or 5-ASA compounds by azo reduction.
2 . The method of claim 1 , wherein the subject has colitis.
3 . The method of claim 1 , wherein the subject has ulcerative colitis or Crohn's disease.
4 . The method of claim 1 , wherein the subject has or is at risk of pouchitis.
5 . The method of any one of claims 1 to 4 , wherein the agent is a compound of the formula:
where R 1 , R 2 , and R 3 are independently hydrogen, halogen, or C1 to C4 alkyl, and R 4 is:
where R 5 is selected from hydrogen, halogen, and C1 to C4 alkyl; or R 4 is:
where R 6 , R 7 , and R 8 are independently hydrogen, halogen, or C1 to C4 alkyl.
6 . The method of claim 5 , wherein the compound is a 4-aminophenylacetic acid azo bonded dimer.
7 . The method of claim 5 , wherein the compound is 5-(4-carboxymethyl-phenylazo)-2-hydroxy-benzoic acid.
8 . The method of claim 5 , wherein the composition comprises a mixture of 5-(4-carboxymethyl-phenylazo)-2-hydroxy-benzoic acid and 4-acetylAPAA or 4-APAA
9 . The method of any one of claims 1 to 8 , wherein the pharmaceutical composition comprises:
at least one stabilizer or surfactant,
at least one thickener or foaming agent, and
at least one suspending or a solubilizing agent.
10 . The method of claim 9 , wherein:
at least one of the stabilizer or surfactant is selected from cetyl alcohol, coconut oil, stearic acid, hydroxypropyl methylcellulose, steric acid, citric acid, disodium ethylenediaminetetraacetic acid, and castor oil; and/or
at least one of the foaming agent or thickener is selected from poloxamer F68, polyoxyl stearyl ether, carbomer, polyethylene glycol, caprylic glycerides, cellulose, xanthan gum, and agar; and/or
at least one suspending or solubilizing agent is selected from propylene glycol, glycerine, emulsifying wax, and a solvent optionally selected from one or more of water and alcohol.
11 . The method of claim 9 or 10 , wherein
the at least one stabilizer or surfactant is about 0.01 to about 0.1%, and optionally about 0.05%, by weight,
the at least one thickener or foaming agent is about 0.05% to about 4% by weight, and
the at least one suspending or solubilizing agent is about 0% to about 30% by weight.
12 . The method of any one of claims 1 to 11 , wherein the pharmaceutical composition is a foam or foamable composition.
13 . The method of claim 12 , wherein the foam or foamable composition comprises a propellant.
14 . The method of any one of claims 1 to 11 , wherein the pharmaceutical composition is a gel or emulsion.
15 . The method of any one of claims 1 to 11 , wherein the pharmaceutical composition is a suppository.
16 . The method of any one of claims 1 to 11 , wherein the pharmaceutical composition is a rectal suspension.
17 . The method of any one of claims 1 to 16 , wherein the subject is suffering from acute pouchitis.
18 . The method of any one of claims 1 to 16 , wherein the subject is suffering from chronic pouchitis.
19 . The method of claim 17 or 18 , wherein the composition is administered during a cycle of antibiotic treatment, or between cycles of antibiotic treatment.
20 . The method of claim 17 or 18 , wherein the composition is administered as an alternative to antibiotic therapy.
21 . The method of any one of claims 17 to 20 , wherein the composition is administered with probiotic therapy.
22 . The method of any one of claims 1 to 21 , wherein the subject has pouchitis that is in remission.
23 . The method of claim 22 , wherein the composition is administered with probiotic therapy.
24 . The method of any one of claims 1 to 16 , wherein the subject is suffering from antibiotic refractory pouchitis.
25 . The method of claim 24 , wherein the composition is administered with probiotic therapy.
26 . The method of any one of claims 1 to 16 , wherein the pharmaceutical composition is administered after a surgical procedure that forms the ileo-anal pouch, and prior to development of pouchitis.
27 . The method of claim 26 , wherein the subject further receives probiotic therapy.
28 . The method of any one of claims 1 to 27 , wherein the composition is administered at least once daily.
29 . The method of claim 28 , wherein the composition is administered for at least one week.
30 . A pharmaceutical composition for rectal administration of a 4-AAPA azo compound comprising:
an effective amount of a 4-AAPA azo compound,
at least one stabilizer or surfactant,
at least one thickening or foaming agent, and
at least one suspending or solubilizing agent.
31 . The pharmaceutical composition of claim 30 , further comprising a propellant.
32 . The pharmaceutical composition of claim 30 or 31 , wherein:
at least one of the stabilizer or surfactant is selected from cetyl alcohol, coconut oil, stearic acid, hydroxypropyl methylcellulose, steric acid, citric acid, disodium ethylenediaminetetraacetic acid, and castor oil;
at least one of the foaming agent or thickener is selected from poloxamer F68, polyoxyl stearyl ether, polyethylene glycol (PEG) 6 caprylic glycerides, cellulose, xanthan gum, and agar; and
at least one suspending or solubilizing agent is selected from propylene glycol, glycerine, emulsifying wax, and solvents optionally selected from water and/or alcohol.
33 . The pharmaceutical composition of claim 32 , wherein:
the at least one stabilizer or surfactant is about 0.01 to about 0.1% by weight, and optionally about 0.05% by weight,
the at least one thickener or foaming agent is about 0.05 to about 4% by weight, and
the at least one suspending or solubilizing agent is about 0 to about 30% by weight.
34 . The pharmaceutical composition of claim 33 , further comprising a propellant or propelling agent at from about 5% to about 50% by weight
35 . The pharmaceutical composition of any one of claims 30 to 34 , wherein the pharmaceutical composition is a foam or foamable composition.
36 . The pharmaceutical composition of claim 35 , wherein the pharmaceutical composition is a propelling foam or foamable composition dispersed with a propellant.
37 . The pharmaceutical composition of any one of claims 30 to 33 , wherein the pharmaceutical composition is a gel or emulsion.
38 . The pharmaceutical composition of claim 37 , wherein the pharmaceutical composition is a rectal suspension.
39 . The pharmaceutical composition of any one of claims 30 to 33 , wherein the pharmaceutical composition is dispersed in a suppository base.